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ABSTRACT
Introduction: Currently, we lack understanding of the
content, quality and impact of patient decision aids to
support decision-making between medical and surgical
methods of early abortion. We plan to undertake a
systematic review of peer-reviewed literature to identify,
appraise and describe the impact of early abortion
method decision aids evaluated quantitatively (Part I),
and an environmental scan to identify and appraise
other early abortion method decision aids developed in
the US (Part II).
Methods and analysis: For the systematic review,
we will search PubMed, Cochrane Library, CINAHL,
EMBASE and PsycINFO databases for articles
describing experimental and observational studies
evaluating the impact of an early abortion method
decision aid on women’s decision-making processes
and outcomes. For the environmental scan, we will
identify decision aids by supplementing the systematic
review search with Internet-based searches and key
informant consultation. The primary reviewer will
assess all studies and decision aids for eligibility, and a
second reviewer will also assess a subset of these.
Both reviewers will independently assess risk of bias in
the studies and abstract data using a piloted form.
Finally, both reviewers will assess decision aid quality
using the International Patient Decision Aid Standards
criteria, ease of readability using Flesch/Flesch-Kincaid
tests, and informational content using directed content
analysis.
Ethics and dissemination: As this study does not
involve human subjects, ethical approval will not be
sought. We aim to disseminate the findings in a
scientific journal, via academic and/or professional
conferences and among the broader community to
contribute knowledge about current early abortion
method decision-making support.
Trial registration number: This protocol is
registered in the International Prospective Register of
Systematic Reviews (CRD42015016717).
BACKGROUND
In the USA, over 1 million women experience
an induced abortion each year,1 and a
majority (64%) of these abortions occur
during early pregnancy (ie, before 9 weeks’
gestation).2 Over a decade ago, mifepristone
was approved by the US Food and Drug
Administration for medical management of
early abortion,3 affording women a choice
between medical and surgical procedures.i
These methods have comparable success
rates, but encompass quite different pro-
cesses. Accordingly, women’s preferences and
circumstances are paramount in the choice
between early abortion methods.3 Some
women favour medical abortion because they
perceive it to be more natural, want to avoid
surgery or value the privacy of the home
environment.4–7 Other women prefer surgical
abortion because of the comfort and finality
of the procedure being completed in a single
clinic visit, their preference for anaesthesia or
their desire not to see the fetus.5 8 9
Research has documented the significant
value women place on having a choice
between medical and surgical abortion,7–11
and on receiving information to support
their informed decision-making.12–14 Despite
Strengths and limitations of this study
▪ Uniquely, this study combines a standard sys-
tematic review with an environmental scan much
broader in scope.
▪ Our methodology will enable a comprehensive
understanding of the early abortion method deci-
sion aids available to women and their content,
quality and impact.
▪ Although informed by the broader goals of this
work, one weakness of the study is that the
environmental scan is limited to a search of deci-
sion aids developed in the USA.
iAlthough both methods are approved federally,
differences in state-level regulations has made access to
early abortion services more variable.1
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women’s articulated desire for trusted resources, scant
research has evaluated the content or quality of informa-
tion available to facilitate women’s early abortion method
decision-making. Evidence from the UK indicates that
some information materials designed for this purpose are
inadequate, unbalanced and difficult to read.15 However,
we are not aware of equivalent research in the USA or else-
where. Such research is particularly important in the USA
where abortion is simultaneously a highly prevalent and
yet highly stigmatized16 procedure, and where there
remains widespread misinformation,17 18 poor access to
services,1 and broad variability in abortion counselling
practices.
Counselling about abortion methods has the potential
to overcome shortcomings in the quality and compre-
hensiveness of information materials. However, although
women in the USA tend to report satisfaction with abor-
tion counselling generally,19 current information provi-
sion about available methods may limit informed,
values-consistent decision-making. Indeed, there is evi-
dence that some adolescent medicine providers have
poor knowledge about the safety and effectiveness of
medical abortion,20 and that some front-line health
workers and social service providers feel they lack the
necessary skills and information to adequately support
women when considering early abortion.21 Studies have
also found that healthcare providers have not disclosed
information about available second trimester abortion22
or ectopic pregnancy treatment options,23 potentially
delaying women’s care or exposing them to unnecessary
risk. It is unsurprising that in a recent qualitative study
of 22 early medical abortion patients, women’s beliefs
about surgical abortion were often inaccurate.4 Similarly,
a recent survey of 67 women who had recently experi-
enced early surgical abortion found that 78% overesti-
mated the health risks of the procedure.24
On the basis of the evidence described above, several
authors have called for the development of evidence-
based educational interventions to enable women to
make quality and unbiased choices about early abortion
methods.24 25 One such intervention, the decision aid, is
designed for this purpose. Specifically, decision aids are
intended to help patients participate in making delibera-
tive choices among healthcare options based on quality
evidence and their preferences.26 Decision aids have
been shown to improve patients’ knowledge of options,
accurate expectations of possible benefits and harms
and participation in decision-making as well as the align-
ment between patients’ choices and their values.26
Accordingly, implementation of a decision aid on early
abortion methods has potential to address current defi-
ciencies in information provision and counselling in the
USA, particularly in areas with growing restrictions on
abortion services.1
Three previous systematic reviews26–28 consistently
identified only one study evaluating a decision aid on
early abortion methods. This study, which was conducted
in the UK in 2002, evaluated a one-page paper decision
aid that described surgical and medical methods of early
abortion.29 The study found that the 163 women rando-
mised to use the decision aid had better knowledge and
felt more informed than the 165 women randomised to
receive usual care.30 While this study speaks to the poten-
tial of a decision aid in this clinical context, this particu-
lar tool has limited suitability for the contemporary US
context due to sociopolitical and cultural differences in
the provision of early abortion care31 32 and develop-
ments in evidence over the past decade.3 Whether other
early abortion method decision aids—especially those
relevant to the contemporary US context—have been
developed and evaluated using non-randomised study
designs, or have been developed but not evaluated quan-
titatively, remains unclear due to the scope of previous
systematic reviews.
Ultimately, an inventory of available early abortion
method decision aids, together with a summary of their
quality and impact, would enhance our understanding of
the decision support available to women choosing
between medical and surgical early abortion. It would
also elucidate necessary next steps for overcoming
current limitations in information provision and counsel-
ling, and women’s knowledge deficits, through imple-
mentation of a patient decision aid in the USA. The aim
of this paper is to describe the protocol for a two-part
study designed to identify existing decision aids and sum-
marise evidence of their content, quality and impact.
OBJECTIVES AND RESEARCH QUESTIONS
This study will comprise a systematic review (SR) to iden-
tify, appraise and describe the impact of early abortion
method decision aids that have been evaluated quantita-
tively and published in peer-reviewed outlets (part I)
and an environmental scan (ES) of the grey literature to
identify and appraise other early abortion method deci-
sion aids developed in the USA (part II). As this study
does not involve human subjects, no ethical approval
will be sought. This study will address several research
questions (see table 1).
METHODS: SYSTEMATIC REVIEW (PART I)
This systematic review protocol was registered on 12
February 2015 with the International Prospective
Register of Systematic Reviews (CRD42015016717) and
adheres to PRISMA-P (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses protocols).33
Moreover, we intend to adhere to the PRISMA method-
ology when reporting on this systematic review.30
Eligibility criteria
Study design
Studies must be randomised controlled trials (ie, individ-
ual, crossover or cluster), non-randomised studies, cohort
studies, case–control studies, before-and-after studies (ie,
controlled or uncontrolled), interrupted-time-series
studies or repeated measures studies.34 We will exclude
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studies that do not have a comparison group (eg, case
series, case reports).
Participants
Study participants must be women who are eligible for
medical and surgical abortion (as defined by trialists)
and who are facing a decision about method of early
abortion. We will exclude studies involving women who
are ineligible for medical and/or surgical abortion, who
are making a hypothetical decision, or who are facing a
decision about spontaneous abortion (ie, miscarriage).
Intervention
The intervention studied should have been a publicly
available (ie, free) decision aid that compared medical
and surgical abortion, and developed after 2000, when
medical abortion became legal in the USA.35 Decision
aids that include a third ‘no treatment’ option (ie, con-
tinuing the pregnancy or adoption) will be included if
they also compare the two methods of early abortion.
We will adopt the Cochrane Collaboration definition of
a decision aid (see box 1).26
For the purpose of this review, ‘implicit methods to
clarify values’ are defined as methods that prompt delib-
eration about options or attributes of options,36 such as
a table enabling direct comparison of the features or
outcomes associated with the options (eg, success rates,
adverse effects) or a description of the options in
“enough detail that clients can imagine what it is like to
experience the physical, emotional, and social effects
and/or guide clients to consider which benefits and
harms are most important to them.”26 The decision aid
may be designed for use before, during, or after a
healthcare appointment or independent of any health-
care appointment, and may be in any format (eg,
pamphlets, booklets, videos, DVDs, interactive websites,
static websites, electronic documents, smartphone
mobile applications (‘apps’)).37 The decision aid may be
published in any language and could have been created
for women in any country.
We will exclude studies of interventions that do not
meet the above definition of decision aid, including
standard health education materials. We will also
exclude interventions that are not publicly available and
those not designed primarily for women facing the deci-
sion (eg, clinical guidelines).
Comparison
The comparison studied may comprise usual care, no
intervention (or baseline) or a non-decision aid inter-
vention. We will exclude studies that either do not
include a comparison group or, in the case of before-
and-after studies, interrupted-time-series studies and
repeated measures studies, that do not have a clearly
defined intervention timeframe.
Outcomes
Studies must provide data on at least one outcome
related to the decision-making process or decision-
making outcome, whether reported by the woman, a
provider and/or a third party (see table 2). Our primary
outcome is decision quality, defined as the extent to
which a decision is informed and based on personal
values.38
Date of study
Based on the intervention inclusion criteria we will
exclude studies published before 2000.
Data sources and search strategy
We will search the following electronic bibliographic
database: PubMed (see box 2), The Cochrane Library,
CINAHL, EMBASE and PsycINFO using, where appro-
priate, medical subject heading (MeSH) terms: “abor-
tion, induced”, “choice behavior”, “patient education”,
“decision support techniques” and “decision making”
and/or key words with Boolean operators (see online
supplementary appendix 1). We will not apply any lan-
guage limits. We will search for studies published since
January 2000. We will also search the trial registry
Box 1 Decision aid definition (Reproduced from Stacey
et al, p. 826)
“(I)nterventions designed to help people make specific and delib-
erative choices among options (including the status quo), by
making the decision explicit and by providing (at the minimum)
(a) information on the options and outcomes relevant to a
person’s health status and (b) implicit methods to clarify values.”
Table 1 Study research questions
Research question SR ES
What early abortion method decision aids have been evaluated quantitatively and published in peer-reviewed
outlets?
✓
What other early abortion method decision aids have been developed for use in the USA? ✓
What is the impact of early abortion method decision aids on women’s decision-making processes and outcomes? ✓
What is the quality of early abortion method decision aids as measured by the International Patient Decision Aid
Standards?
✓ ✓
How does the content of early abortion method decision aids developed in the USA support quality
decision-making?
✓
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ClinicalTrials.gov and manually search the reference lists
of all included articles for additional studies conducted
or published since January 2000.
Additionally, any decision aid identified during the
environmental scan (see below) that has been evaluated
quantitatively and published in peer-reviewed outlets will
be considered for inclusion in the systematic review.
Data screening
Search results will be downloaded and managed in
Mendeley 1.13.1. After duplicate entries are removed,
the primary reviewer (KD) will screen the titles and
abstracts of all identified articles and classify each as
potentially eligible or ineligible for inclusion. A second
reviewer (RT) will independently screen random
samples of 10% of the titles and abstracts in each classifi-
cation. Inter-rater reliability will be measured using
Cohen’s κ.39 If significant discrepancies are observed in
either classification (ie, κ<0.7), the second reviewer will
screen all titles and abstracts, and discrepant classifica-
tions will be resolved by discussion.
Full-text review
The primary reviewer will perform full-text review of all
potentially eligible articles and classify each as eligible or
ineligible for inclusion. The reason for ineligibility will
be recorded. If a classification cannot be made based on
full-text review, attempts will be made to contact the
study authors for clarifying information. The second
reviewer will independently review a random sample of
10% of the full-text articles and inter-rater reliability will
be assessed. If major discrepancies in classification are
identified (ie, κ<0.7), the second reviewer will perform a
full-text review of all articles and discrepant classifica-
tions will be resolved by discussion. Finally, the primary
reviewer will contact the author of each included study
to inquire about any related studies (eg, study protocols,
companion studies).
Data abstraction
Both reviewers will use a piloted form (see online
supplementary appendix 2) to abstract data (ie, study
design, participant characteristics, decision aid format
and administration, findings, etc) from all studies
deemed eligible for inclusion. We will also abstract data
on other relevant outcomes measured by these studies.
All abstracted data will be compared and disagreements
resolved by discussion. If multiple publications describe a
single study, authors will consider these as a single study.
Study and evidence quality appraisal
Both reviewers will independently assess the methodo-
logical quality of included studies using the Cochrane
Effective Practice and Organisation of Care Group’s
(EPOC) criteria for randomised, non-randomised
studies, before-and-after, interrupted-time-series studies
or repeated measures studies40 and the Newcastle-
Ottawa Scale for observational studies.41 Using EPOC
criteria, we will apply a judgment of ‘unclear risk’, ‘low
risk’ or ‘high risk’ to nine categories for each rando-
mised, non-randomised and before-and-after study, and
for seven categories for each interrupted-time-series and
repeated measures study.40 Using the Newcastle-Ottawa
Scale, we will award each study a maximum of nine
points for items related to selection, comparability and
outcome assessment bias.41
Both reviewers will also independently apply the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) criteria to rate the quality of
evidence (high, moderate, low, very low) across studies
for the primary outcome, decisional quality, using
GRADEprofiler software (see online supplementary
appendix 3).42 We will assess key factors that can down-
grade the quality of evidence (eg, methodological
quality, directness of evidence, heterogeneity, precision
of effect estimates and risk of publication bias) and
upgrade the quality of evidence (ie, magnitude of effect,
Box 2 PubMed Search Strategy
Search Terms
(“abortion, induced” [MeSH] OR “pregnancy termination” [tiab]
OR “termination of pregnancy” [tiab] OR “abortion” [tiab]) AND
(“choice behavior” [MeSH] OR “decision support techniques”
[MeSH] OR “patient education” [MeSH] OR “decision making”
[MeSH] OR “decision support” [tiab] OR “decision aid” [tiab] OR
“decision aids” [tiab] OR “informed choice” [tiab])
Table 2 Potential outcomes and their definitions
Outcome Definition
Decision quality The extent to which a decision is informed and based on the patient’s personal values38 55 56
Decision self-efficacy A patient’s degree of confidence or belief in one’s ability to make decisions57
Decision aid utility The extent to which a decision aid is considered useful for preparing a patient to communicate
with his/her provider and to make a health decision58
Decisional conflict A patient’s degree of uncertainty about the right course of action to take (eg, due to to feeling
uninformed, unclear about personal values and/or unsupported in decision-making)59 60
Decision-making role
concordance
The alignment between a patient’s preferred and assumed decision-making role61 62
Shared decision-making The extent to which a healthcare decision is made collaboratively by patient and provider63
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dose–response gradient and ability of the study to limit
bias and control for confounding).43 The quality of evi-
dence can be downgraded or upgraded by one level or
two levels to eventually describe a ‘high’, ‘moderate’,
‘low’ or ‘very low’ assessment of our confidence in the
estimate of effect. The methodological and evidence
quality assessments made by the reviewers will be com-
pared and disagreements resolved by discussion.
Decision aid quality appraisal
Both reviewers will independently assess the quality of
decision aids evaluated in included studies using the
International Patient Decision Aid Standards (IPDAS)
checklist. This tool has 59 items which evaluate the
domains of content, development process and effective-
ness for decision aids not involving tests.44 For each deci-
sion aid, we will assess each checklist item as ‘yes’ or ‘no’
or ‘not applicable’, with the final score ranging from 0
to 50 (Internet-based decision aids and those which inte-
grate narratives have 6 and 3 additional items, respect-
ively). Discrepant classifications will be resolved by
discussion.
In addition, the primary reviewer will assess the read-
ability and reading ease of text-based decision aids using
the Flesch-Kincaid test.45 46 The Flesch-Kincaid Grade
Level measures textual difficulty based on words per sen-
tence and syllables per word, and presents a score as a
US grade level. The Flesch Reading Ease Scale uses
average sentence length and the average number of syl-
lables per word to calculate a score on a scale of 0 (very
hard to read) to 100 (very easy to read).
Analysis of decision aid impact
We will quantitatively synthesise the findings from
included studies if they are sufficiently homogeneous.
We will calculate weighted treatment effects with 95%
CIs. We will calculate risk ratios for dichotomous data
and mean differences for continuous data. We will pool
the results across studies with comparable outcome mea-
sures using a random-effects meta-analysis. When neces-
sary data are available, we will compute standardised
outcome scores to have a mean of 50 with SD of 10 for
ease of descriptive comparison. If effect sizes cannot be
calculated for the key outcomes due to inadequate infor-
mation, we will contact the study authors for additional
data. For each outcome, data will be synthesised and
analysed using the statistical software, RevMan 5.1, as
indicated by the Cochrane Handbook of Systematic
Reviews of Interventions.47 Heterogeneity will be
assessed and considered substantial if the I2 statistic is
>50% and the χ2 test p value is <0.10.48 If heterogeneity
exists for a given outcome, we will seek to understand its
source and conduct quantitative analysis on homogen-
ous subgroups of studies. If relevant, the results of the
methodological quality assessment will be used to
perform sensitivity analyses to test the effect of omitting
studies at high risk of bias. If meta-analysis is not pos-
sible, we will perform a narrative analysis and present
summary information on all study characteristics and
the primary outcome in text and tabular form.
We will explore the potential for publication bias visu-
ally using funnel plots if 10 or more studies are
included.49 If study protocols have been published, we
will also compare outcomes reported in the protocol
and the published report to assess for selective outcome
reporting.
METHODS: ENVIRONMENTAL SCAN (PART II)
Given the absence of quality standards for conducting
environmental scan, our approach was informed by the
methods of previous environmental scans about decision
aids and/or shared decision-making.50 51
Eligibility criteria
Intervention
The intervention must be a decision aid, as described
above. For the environmental scan only, the decision aid
must be written in English and have been created by a
source in the USA for women residing in the USA.
Data sources and search strategy
The Internet will comprise the primary data source for
identifying decision aids for inclusion in the environ-
mental scan. The Internet will be used both to identify
relevant web-based decision aids and to identify refer-
ences to non-web-based decision aids. We will execute
four searches using the Google Advanced Search ‘all
these words’ function and the following key word
strings: (1) abortion decision aid, (2) abortion options, (3)
pregnancy termination options and (4) medical or surgical
abortion. We will select ‘USA’ in the ‘region’ category to
refine the search. Cookies will be disabled before the
search to avoid inadvertent bias. Efforts will be made to
obtain any relevant documents that elaborate on the
development or use of the decision aids. This may
involve searching other sections of a multipage website
and/or contacting the developers of the tools directly to
request further information. To identify smartphone
apps, we will search the two most frequently used
Internet-based app stores, the English-language, US-
based Apple app store and Google Play.52 We will use
the key word abortion in the search field for both stores.
We will complement the Internet search by consulting
organisations (eg, National Abortion Federation,
Abortion Care Network, Reproductive Health Access
Project, Planned Parenthood Federation of America,
Provide and Society for Family Planning) and key infor-
mants (eg, women, researchers, clinicians, policymakers
and/or advocates in the field). We will contact these
organisations and individuals to solicit known examples
of relevant decision aids (see online supplementary
appendix 4) and will continue this consultation strategy
until we determine that no new decision aids are likely
to be identified.
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Additionally, any decision aid identified during the sys-
tematic review will be considered for inclusion in the
environmental scan.
Screening and full review
Owing to the dynamic nature of the Internet, the screen-
ing and full review of Internet pages identified in the
Google searches will be conducted concurrently. The
primary reviewer will perform the first search string,
archive the list of the first 100 results (ie, web address,
page title, brief description and date searched),53 and
classify each as potentially useful or not useful for identi-
fying a decision aid. The reviewer will then open all
pages considered potentially useful, archive each full
page and if the page comprises or contains a decision
aid, classify that tool as eligible or ineligible for inclusion.
The reason for exclusion will be recorded. If the page
contains only a reference to a decision aid, the primary
reviewer will attempt to obtain a copy by contacting the
source at a later time and, if successful, will then deter-
mine the eligibility of the decision aid for inclusion.
Decision aids that cannot be obtained will be noted. This
process will be replicated for each of the other three
search strings.
For smartphone apps, the primary reviewer will
archive and assess for eligibility the first 50 results on the
general app description page of each Internet-based app
store. The reviewer will then open, archive and assess
the description of potentially eligible apps. The reviewer
will download all apps considered potentially eligible to
a smartphone and then classify each as eligible or ineli-
gible for inclusion. At each stage, the reason for exclu-
sion will be recorded.
The primary reviewer will use the same screening and
review process to assess the eligibility of decision aids
suggested by key informants.
Using the archives created by the primary reviewer,
the second reviewer will independently open and assess
random selections of 10% of the websites, apps and sub-
sequently sourced decision aids classified by the primary
reviewer as eligible and 10% of those classified as ineli-
gible. The second reviewer will also archive the full page
of each website opened for assessment (ie, included and
excluded) in case the content has been modified since
the primary reviewer undertook screening and full
review. Inter-rater reliability will be measured using
Cohen’s κ.39 If significant discrepancies are observed in
either classification (ie, κ<0.7) that are not due to
dynamic content, the second reviewer will complete
screening and full review for all websites, apps and sub-
sequently sourced decision aids, and the discrepant clas-
sifications will be resolved by discussion.
Data abstraction
Both reviewers will use a piloted form to abstract data
from all decision aids (eg, characteristics, format and
source) that meet inclusion criteria (see online supple-
mentary appendix 5).
Decision aid quality appraisal
Both reviewers will independently evaluate the quality of
the decision aids using the IPDAS checklist and the
Flesch-Kincaid test, as described above.
Decision aid content analysis
We will analyse the content and presentation of informa-
tion in included decision aids using methods from
directed content analysis54 with an emphasis on distin-
guishing similarities and differences across the body of
included tools. We will focus on identifying patterns in
content and presentation relevant to promoting quality
decision-making such as inclusion or omission of par-
ticular method features, word choice, framing of lan-
guage about women’s decision-making role and values
clarification approaches. Data collection and analysis will
follow an iterative process, whereby the coding structure
and emerging themes will continuously be expanded
and refined as more data is collected and analysed. The
primary reviewer will lead the qualitative data collection
and analysis process, and intermittently consult with the
secondary reviewer with respect to the coding structure
and emergent themes.
CONCLUSION
This protocol describes a study that will provide evi-
dence about the content, quality and impact of early
abortion method decision aids, and produce an inven-
tory of appraised tools relevant to the US context. We
intend to publish the results in academic and non-
academic outlets to contribute knowledge about current
early abortion method decision-making support. In
doing so, we hope to elucidate relevant next steps for
attempting to overcome current limitations to counsel-
ling and women’s knowledge deficits through implemen-
tation of a patient decision aid in the US.
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